Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

Sponsor
University Hospital, Ghent
Study ID
NCT02399410
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • perioperative chemotherapy plus bevacizumab — DRUG
    preoperative and postoperative combination chemotherapy with bevacizumab
  • cytoreductive surgery — PROCEDURE
    complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
  • Intraperitoneal Oxaliplatin — DRUG
    Pump-driven intraperitoneal administration of oxaliplatin

Study Details

The Bev-IP trial is designed to assess the feasibility and efficacy of a combined treatment consisting of perioperative combination chemotherapy with the vascular endothelial growth factor A inhibitor bevacizumab and cytoreductive surgery with intraperitoneal oxaliplatin.

Key Dates

First listed
Mar 26, 2015
Start date
Nov 4, 2015
Status verified
Jan 2024
Primary completion
Nov 9, 2023
Completion
Nov 9, 2023

Study Design

Enrollment
60 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: bevacizumab and CRS with oxaliplatin
    Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin

Primary Outcome Measure

surgical morbidity and mortality [ Time Frame: until 3 months after surgery and intraperitoneal chemotherapy ]

Related Studies